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Abstract
The present review summarizes current aspects on how to perform noninvasive microvolt
T-wave alternans (mTWA) testing in clinical practice. The focus is on methodologic issues
such as patient-related, or technical aspects, and interpretation of the results. Special attention
is given to the different sources of noise that may interfere with mTWA assessment. The role of
beta-blocker therapy and its potential effect on mTWA is discussed as well. In the first clinical
studies of mTWA, a high rate of indeterminate test results was observed. In this respect,
patient-related indeterminacy has been demonstrated to be associated with an increased mor-
tality and such tests are thus regarded as “abnormal” whereas technically inadequate tests are
classified as indeterminate. Since mTWA evolves over time in patients with structural heart
disease, the “optimal timing” for mTWA assessment is rather in the chronic phase than in the
acute setting of heart disease. (Cardiol J 2008; 15: 288–292)
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Introduction
Several studies have recently proven that pri-
mary preventive therapy of sudden arrhythmoge-
nic death is possible in selected patients with con-
gestive heart failure, particularly in the setting of
ischemic cardiomyopathy [1, 2]. However, many
clinicians agree that more accurate identification of
patients at arrhythmogenic risk is warranted. Mi-
crovolt level T-wave alternans (mTWA) has recen-
tly been proposed to assess abnormalities in ven-
tricular repolarization favoring the occurrence of
reentrant arrhythmias [3, 4]. In 1994, a first clini-
cal study [5] convincingly demonstrated that mTWA
is closely related to arrhythmia induction in the
electrophysiology laboratory as well as to the oc-
currence of spontaneous ventricular tachyarrhy-
thmias during follow-up [5]. More recently, a number
of clinical studies has examined its clinical applica-
tion [6–14].
However, several methodological issues have
been a matter of debate, including interpretation and
potential consequences of so-called “indetermina-
te” test results as well as the question of repetiti-
ve re-testing of patients who may be at high risk
according to their reduced ejection fraction but have
a negative mTWA test.
The present review summarizes currently availa-
ble clinical data on mTWA with a particular focus on how
to perform the test and how to interpret its results.
Definition and pathophysiological
aspects of mTWA
T-wave alternans is defined as 2:1 beat-to-beat
changes in the amplitude of the T-wave. Whereas
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visible “macroscopic” T-wave alternans (TWA) has
been associated with a high risk of ventricular ta-
chyarrhythmias in patients with the congenital long
QT syndrome [15] or other clinical disorders, this
phenomenon is rarely observed in clinical practice
[16, 17]. With the development of new computer
processing techniques, the phenomenon of micro-
volt level TWA was first demonstrated in an expe-
rimental study by Adam, Smith and coworkers
[3, 18]. Recent experimental and clinical studies
have provided new insights into the genesis of this
phenomenon [4, 19–21]. Briefly, with increasing
heart rate, action potential duration shows discor-
dant prolongation in different regions of the myocar-
dium finally resulting in repolarization alternans
with opposite phase between neighboring cells (so-
called discordant alternans). This creates increased
spatial dispersion of repolarization associated with
unidirectional conduction block, reentry, and finally
the occurrence of ventricular fibrillation [4]. On the
cellular level, TWA is accompanied by inhomogene-
ities in the calcium transient indicating that Ca2+ ions
play a key role in the genesis of TWA [22–24].
Methodology of mTWA
The spectral methodology of mTWA analysis
involves a graded increase of heart rate in order to
provoke this electrophysiological phenomenon. In
general, heart rate elevation is performed using
bicycle or treadmill exercise. Some investigators
have performed mTWA assessment using infusion
of positive chronotropic agents or cardiac (atrial)
pacing [25, 26]. In detail, during increasing heart
rate, sequential ECG cycles are aligned to their QRS
complex and the amplitude of the T waves at a pre-
defined point t are measured. Subsequently this
beat-to-beat series of amplitude fluctuations —
devided in 128-beat segments —– are subjected to
spectral analysis using fast Fourrier transformation.
Using different time points of the T-wave, multiple
spectra are generated and then averaged to a com-
posite spectrum. The alternans voltage (unit: µV)
represents the square root of the alternans power,
and represents the voltage difference between the
overall mean beat and the even (or odd) numbered
mean beats. The alternans ratio (K score) is a me-
asure of the significance of alternans and is calcu-
lated as the ratio of alternans power divided by the
standard deviation of the noise [27]. TWA manife-
sts itself as a pronounced peak which is visible in
the power spectrum at 0.5 cycles/beat. The greater
the power, the higher is the alternans voltage. An
alternans voltage exceeding 1.9 µV with the alter-
nans ratio K (indicator of the significance of the
measurement) being ≥ 3 min is defined significant.
To be defined as positive, alternans has to be su-
stained for ≥ 2 min. A typical example for a positi-
ve mTWA test is depicted in Figure 1.
Preparation for “successful”
mTWA assessment
The quality of the data collected is pivotal in
the precise and correct interpretation of the test re-
sults. Specialized electrodes have, therefore, been
Figure 1. Alternans voltage in a patient with moderately reduced left ventricular function and a history of syncope
following myocardial infarction. Note the increase of T-wave alternans voltage with increasing heart rate (HR).
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developed that are devided in multiple segments for
recording of ECG signals as well as measurement
of impedance and respiratory activity (Microvolt
Alternans Sensors™, Cambridge Heart Inc., Bed-
ford, MA, USA). Through an adaptive averaging
method, noise can be cancelled and a composite low-
noise ECG signal is produced. In addition, careful
skin preparation prior to electrode placement has
been shown to significantly reduce artifact noise
levels by decreasing electric impedance; this pre-
paration includes shaving hair and slight skin abra-
sion resulting in reduction of skin-to-lead impedan-
ce. Further artifact reduction can be obtained by
placing the arm electrodes away from the pectoral
muscles with the patients loosely resting their arms
instead of “cramping” to the hand grips. Careful
attention should be given to the exercise protocol:
the increase in heart rate should be slow, particular-
ly in the heart rate window between 90 and 110 bpm
— which should last 3–5 min in order to have 2 min
with the heart rate between 105 and 110 [27, 28].
Classification of mTWA test results
The classification of mTWA is based on its
magnitude, its relationship to heart rate, the alter-
nans ratio, and assessment of potential artifacts.
Based on these measures, the test is classified as
positive (= pathological), negative (= normal) or
indeterminate; the latter means that the test cannot
be classified as positive or negative for several poten-
tial reasons: (1) there is alternans, but it is not susta-
ined, (2) noise levels are too high and may obscure
the mTWA result, (3) there are too many “bad be-
ats”. Bad beats are defined as either premature beats
(> 10%), or beats with a different morphology (cor-
relation < 0.9) compared to normal template QRS
complexes. To better classify the mTWA test, diffe-
rent rules have been developed which are based on the
different criteria mentioned above [28]. The so-called
B-rules have recently been used as the standard clas-
sification system by most investigators (Fig. 2).
Potential problems in classifying mTWA
There are some situations, in which determi-
nation of mTWA may be challenging. These inclu-
de: rapid changes in heart rate leading to artifactu-
al alternans; RR interval alternans; ECG lead mal-
function; too rapid increase in heart rate during
exercise; respiration; pedaling artifacts; noise from
musculature; excessive number of ectopic beats. All
of these can result in artifacts and produce “arti-
factual alternans” which may be depicted in the
trend report as sustained alternans. A case collec-
tion of different mTWA recordings including those
with different sources of noise/artifacts is presen-
ted in an excellent paper by Bloomfield et al. [28].
The “indeterminate” mTWA test result
In the first clinical studies the rate of indeter-
minate (i.e. not positive and not negative) test re-
sults averaged about 25%. It also has been demon-
strated that depending on the cause of indetermi-
nacy, the test may have a prognostic value which
has led to categorize patients with positive and in-
determinate tests as “non-negative” or “abnormal”,
being at higher risk than mTWA-negative patients
(“normal” test result) [29]. The reason for classify-
ing a test as indeterminate is, however, of importan-
ce. Whereas an increased number of ventricular pre-
mature beats as well as inability to achieve the tar-
get heart rate (also referred to as “incomplete” test)
may be a harbinger of worse outcome and therefo-
re puts a patient in a higher risk category [28–30],
the occurrence of (muscle) artifacts or electrode
noise — referred to as “technically indeterminate”
has no prognostic value per se. It has thus recently
been proposed that in case of an indeterminate re-
sult the test should be repeated immediately, sin-
ce a significant proportion of patients will have
a classifiable test; such a protocol has been applied
in the ABCD and MASTER-I trials [31, 32].
Figure 2. Classification rules of microvolt T-wave alter-
nans (mTWA); HR — heart rate (modified from [12])
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Medication, bundle branch block,
and mTWA
The influence of certain conditions such as
antiarrhythmic/antiadrenergic medication or intra-
ventricular conduction delay on mTWA have been
and remain a matter of debate. In fact, some stu-
dies have demonstrated the effect of autonomic tone
on mTWA [33–35]. It could be demonstrated that
alternans voltage amplitude is reduced following IV
administration of metoprolol or sotalol [35] — this
is primarily due to the attenuated heart rate incre-
ase during exercise. However, in most cases a po-
sitive test will not become negative. In several stu-
dies, beta-blockers were not withheld prior to
mTWA testing and in these studies mTWA was
predictive of ventricular tachyarrhythmic events.
It is not known at present whether a decrease in
mTWA voltage translates into a better clinical out-
come with respect to endpoint events. However,
since risk stratification should be performed in the
patients “clinical reality”, i.e. on full protective
medication, the authors propose to perform mTWA
testing on beta-blockers. Another methodologic
controversy relates to the effect of bundle branch
block on mTWA [36, 37]. A recently published pro-
spective study in 386 patients with ischemic car-
diomyopathy and non-sustained ventricular tachy-
cardia demonstrated that patients with bundle
branch block are at high risk irrespective of mTWA
results. However, mTWA was highly predictive of
arrhythmic events in patients with a narrow QRS
complex [37].
Is there optimal timing of
mTWA assessment?
In several studies of patients with chronic he-
art diseases and left ventricular dysfunction or chro-
nic heart failure — both of ischemic and non-ische-
mic origin — mTWA has been shown to be of high
predictive value with respect to arrhythmic events
or mortality. In contrast, there are several studies
in the early (7 days to 3 weeks) post myocardial
infarction period, that consistently showed (1)
a high rate of indeterminate test results, and (2) that
mTWA did not yield significant predictive power [38].
From the data of one well controlled pilot study of
serial mTWA measurements in post-myocardial
infarction patients [39] it can be postulated that the
arrhythmogenic substrate evolves over time and
thus the optimal time frame for mTWA testing may
be something like 3–6 months after an acute
myocardial infarction. But even then, a substantial
proportion of patients who initially will test mTWA
negative may turn to a positive test result later
during the course of their disease. Although there
are currently no prospective data to support this,
is seems prudent to assess mTWA in high-risk pa-
tients on a regular (e.g. 6-monthly) basis. Further
studies are needed in order to define the optimal
timing and the usefulness of repetitive mTWA te-
sting after myocardial infarction as well as in pa-
tients with depressed left ventricular function.
Future of mTWA — new methods
The alternative to exercise-induced spectral
mTWA is the modified moving average (MMA) ana-
lysis [40]. This is a Holter-based method using
a time-domain analytic approach. Basically, MMA
is based on averaging odd and even beats and con-
structing a T-wave template for each group which
are then compared for TWA. The MMA method has
first been used in different smaller patient popula-
tions and recently in two large cohort studies and
seems to provide similar predictive value as com-
pared to the spectral method [41, 42]. In the recen-
tly published REFINE study both methods have
been compared in 322 post myocardial infarction
patients. With respect to the primary endpoint of
cardiac death or resuscitated cardiac arrest, both
methods yielded similar predictive value; in combi-
nation with an autonomic marker (either heart rate
turbulence or baroreflex sensitivity) the hazard ra-
tio for an endpoint event increased significantly [42].
The Holter-based MMA method offers the poten-
tial of mTWA assessment independently from an
exercise test; however, since there is only modest
correlation between the two methods, further stu-
dies are warranted to compare both approaches with
regard to pathophysiological as well as methodolo-
gical issues and to clarify their role in screening
patients with respect to prophylactic therapy with
implantable cardioverter-defibrillators.
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